1. Home
  2. HR vs PRAX Comparison

HR vs PRAX Comparison

Compare HR & PRAX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Healthcare Realty Trust Incorporated

HR

Healthcare Realty Trust Incorporated

HOLD

Current Price

$19.18

Market Cap

7.3B

Sector

Real Estate

ML Signal

HOLD

Logo Praxis Precision Medicines Inc.

PRAX

Praxis Precision Medicines Inc.

HOLD

Current Price

$378.36

Market Cap

7.1B

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
HR
PRAX
Founded
1992
2015
Country
United States
United States
Employees
N/A
N/A
Industry
Real Estate Investment Trusts
Biotechnology: Pharmaceutical Preparations
Sector
Real Estate
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
7.3B
7.1B
IPO Year
2006
2020

Fundamental Metrics

Financial Performance
Metric
HR
PRAX
Price
$19.18
$378.36
Analyst Decision
Hold
Strong Buy
Analyst Count
8
15
Target Price
$19.29
$572.13
AVG Volume (30 Days)
3.8M
383.1K
Earning Date
04-30-2026
05-08-2026
Dividend Yield
5.20%
N/A
EPS Growth
60.77
N/A
EPS
N/A
N/A
Revenue
$1,180,546,000.00
N/A
Revenue This Year
N/A
N/A
Revenue Next Year
$3.14
$7,758.26
P/E Ratio
N/A
N/A
Revenue Growth
N/A
N/A
52 Week Low
$16.28
$37.25
52 Week High
$22.04
$388.00

Technical Indicators

Market Signals
Indicator
HR
PRAX
Relative Strength Index (RSI) 29.10 66.02
Support Level $16.60 $285.26
Resistance Level $20.66 N/A
Average True Range (ATR) 0.38 18.25
MACD -0.21 5.76
Stochastic Oscillator 3.97 94.97

Price Performance

Historical Comparison
HR
PRAX

About HR Healthcare Realty Trust Incorporated

Healthcare Realty Trust Inc is a healthcare facility real estate investment trust. The company focuses on owning, leasing, and managing outpatient facilities and other healthcare properties. The company works to invest in outpatient facilities that are integral to a hospital's operations. It generates all of its revenue in the United States.

About PRAX Praxis Precision Medicines Inc.

Praxis Precision Medicines Inc is a clinical-stage biopharmaceutical company. It is engaged in translating genetic insights into the development of therapies for patients affected by central nervous system disorders characterized by a neuronal excitation-inhibition imbalance. The company applies genetic insights to the discovery and development of therapies for neurological disorders through two proprietary platforms: Cerebrum and Solidus. It has established a diversified, multimodal CNS portfolio with four clinical-stage product candidates across movement disorders and epilepsy, which include Ulixacaltamide, Relutrigine, Vormatrigine, and Elsunersen. The firm operates in only one segment and is focused on discovering and developing therapies for CNS disorders.

Share on Social Networks: